Novel treatments for depression and other neuropsychiatric disorders NEW YORK, March 24, 2022 /PRNewswire/ — Gilgamesh Pharmaceuticals, a mental health-focused biotechnology company developing novel psychedelic-related medicines, today announced the nomination of two lead clinical candidates for the treatment of debilitating neuropsychiatric disorders such as depression, anxiety, PTSD…


Previous articleDelix Therapeutics Closes $30 Million Convertible Note Financing, Enters $10 Million Strategic Credit Facility Option in Partnership with Comerica Bank
Next articleMindset Pharma and Top Psychiatric Research Hospital, CAMH, Enter Innovative Collaboration to Build Molecular Profile of MSP-1014 Compared to Psilocybin